Scott Dunseth Myers
CIK 1356256 · Chief Executive Officer · last filed 2026-02-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.51M
Companies
10
Total Filings
52
Lifetime Open-Market Net
$555.0K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Director | 0 | $15.50 | $0 | $41.1K | 7 | 2026-02-10 |
| ZNTL | Director | 338,795 | $3.75 | $1.27M | $29.4K | 3 | 2025-06-18 |
| Harpoon Therapeutics, Inc. (HARP) Delisted | Director | 0 | $23.01 | $0 | $0 | 13 | 2024-03-11 |
| RNAC | Director | — | $9.51 | — | $0 | 1 | 2023-11-15 |
| VRDN | Chief Executive Officer | 259,500 | $16.35 | $4.24M | $261.8K | 3 | 2023-04-12 |
| Cartesian Therapeutics, Inc. (SELB) Delisted | Director | 80,845 | $0.88 | $71.2K | $0 | 7 | 2023-01-04 |
| Trillium Therapeutics Inc. (TRIL) Delisted | Director | — | $19.86 | — | $0 | 1 | 2021-05-05 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | President & CEO | — | — | — | $0 | 2 | 2020-11-17 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | President and CEO | 56,787 | — | — | $222.7K | 12 | 2018-02-02 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | President and CEO | — | — | — | $0 | 1 | 2016-04-06 |
Recent Filings · Page 5 of 6
52 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-01-16 | Cascadian Therapeutics, Inc. (CASC) Delisted | Mixed | +7,071 | -$13.4K | EDGAR |
| 2017-11-13 | Cascadian Therapeutics, Inc. (CASC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-09-20 | Cascadian Therapeutics, Inc. (CASC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-08-14 | Cascadian Therapeutics, Inc. (CASC) Delisted | Buy (P) | +5,500 | $20.5K | EDGAR |
| 2017-05-16 | Cascadian Therapeutics, Inc. (CASC) Delisted | Buy (P) | +2,800 | $11.2K | EDGAR |
| 2017-04-04 | Cascadian Therapeutics, Inc. (CASC) Delisted | Buy (P) | +2,000 | $8.2K | EDGAR |
| 2017-03-21 | Cascadian Therapeutics, Inc. (CASC) Delisted | Buy (P) | +1,000 | $3.9K | EDGAR |
| 2017-01-31 | Cascadian Therapeutics, Inc. (CASC) Delisted | Buy (P) | +20,500 | $77.0K | EDGAR |
| 2017-01-13 | Cascadian Therapeutics, Inc. (CASC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-08-18 | Cascadian Therapeutics, Inc. (CASC) Delisted | Buy (P) | +45,000 | $51.7K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.